PubMed Health⌕ Search

PubMed · 7666345

[Cardiothoracic ratio].

Abstract

Cardiothoracic ratio has been a useful index of cardiac dilatation, and a value of 50% is generally considered to indicate the upper limit of normal cardiac size. However, this value is not always correct and increases the number of false-positive results, especially in obese or older subjects who may have a misdiagnosis of cardiac enlargement. The maximal transverse diameter of the cardiac shadow of chest X-ray film consists mainly of the diameters of the left ventricle and the right atrium as shown by X-ray computed tomography, but this ratio is influenced by many factors; not only left ventricular dilatation or hypertrophy, but also dilatation of the other cardiac chambers and the aorta, rotation and shift of the heart, respiratory phase, body posture, and measurement errors. In contrast, echocardiography is an accurate method for the diagnosis of cardiac dilatation. This study correlated left ventricular dimension with cardiothoracic ratio in 80 consecutive subjects with normal physical, ECG and Doppler echocardiography examinations. There was no relationship between left ventricular end-diastolic dimension and the cardiothoracic ratio. Chest X-ray is mandatory for initial cardiac examination. However, we must be careful about roentgenographic diagnosis of cardiac dilatation. Cardiac enlargement should be diagnosed by echocardiography, but follow-up and management can be based on chest X-ray films.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Y Hada. 1995. [Cardiothoracic ratio].. https://pubmed.ncbi.nlm.nih.gov/7666345/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The bidirectional genetic causality between immunocyte phenotypes and dilated cardiomyopathy: A bidirectional Mendelian randomization study.

The association between immunocyte phenotypes and dilated cardiomyopathy (DCM) has been explored, however the exact pathogenesis of the relationship between immune cells and DCM is unclear. This bidirectional two-sample Mendelian randomization (MR) research aims to further validate the causal link between 731 immunocyte phenotypes and DCM. Summary statistics from a genome-wide association study data of individuals with European ancestry were utilized, including 1444 DCM cases and 353,937 controls, as well as 3757 European adults for the 731 immunocyte phenotypes. Causal effects were estimated using inverse variance weighted, MR-Egger regression, weight median estimator, weighted mode, and simple mode. Sensitivity analysis was conducted to confirm data robustness and feasibility. Based on the inverse variance weighted findings, 14 immunocyte phenotypes were risk factors for DCM (P&#x2005;<&#x2005;.05, odds ratio [OR]&#x2005;>&#x2005;1), while 15 immunocyte phenotypes exhibited a protective effect on DCM (P&#x2005;<&#x2005;.05, OR&#x2005;<&#x2005;1). The results of reverse MR analysis suggested evidence that DCM occurrence might elevate the levels of 17 immunocyte phenotypes (P&#x2005;<&#x2005;.05, OR&#x2005;>&#x2005;1) and decrease the levels of 9 immunocyte phenotypes (P&#x2005;<&#x2005;.05, OR&#x2005;<&#x2005;1). Our research indicated that CD28 on secreting regulatory T cell could mitigate the occurrence of DCM, and reciprocally, the progression of DCM could reduce the level of CD28 on secreting regulatory T cell. This study confirmed the bidirectional genetic predictive relationship between immunocyte phenotypes and DCM, underscoring the complex interplay between DCM and the immune system.

Cardiomyopathy, Dilated↗

Neuroblastoma presenting with dilated cardiomyopathy.

We report an infant with neuroblastoma who presented with dilated cardiomyopathy. A 3-month-old girl presented with dilated cardiomyopathy diagnosed as stage III neuroblastoma. Since total resection was impossible, chemotherapy was started. Cardiomyopathy was normalized by improvement of neuroblastoma. The prompt improvement of cardiac function following treatment of neuroblastoma suggested that cardiomyopathy in this patient was caused by the increase in catecholamines secreted by neuroblastoma and that reduction in catecholamines by treatment of neuroblastoma led to improvement in the cardiomyopathy.

Cardiomyopathy, Dilated↗